Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Immunological Characterization of Varicella Zoster Virus (VZV) as a Replicating Viral Vector for an HIV Vaccine
EF 2013-14
Résumé
The Varicella-Zoster virus (VZV) vaccine, also known as chickenpox vaccine, has been used to great success in routine immunizations for over 25 years. Unique aspects of this vaccine may, in fact, be useful in developing a vaccine against HIV. After vaccination against VZV, the virus persists in the body in a dormant state causing silent reactivation throughout a person's life. Although silent, this reactivation boosts the immunity and helps to keep the disease in check. This ability to reactivate may be a key factor that we can take advantage of in an HIV vaccine, where one of the principal hurdles is generating a specialized defence army in constant sentinel at the portal of entry of HIV.
Our group has recently tested this strategy in monkeys using VZV as a "transport" vector carrying a "payload" of genes from SIV (Simian Immunodeficiency Virus) - the monkey version of the AIDS virus. Results of this trial are promising, with about a third of vaccinated monkeys demonstrating complete and sustained SIV viral clearance in what may be termed a "Functional Cure". Understanding the mechanisms associated with this effect are a key component of my research project which insights will be used to improve vaccine design.
Although the human VZV vaccine has a well-described safety record, it is important to further investigate its potential as a vector in an HIV vaccine. To do so, we will assess the level of immune activation following vaccination with the empty VZV vector in a cohort in Kenya. This is a critical question, since HIV infects activated immune cells in the mucosa and, in the absence of induced protective immunity, could pose a safety hazard.
This project has significant implications, not only to the development of novel HIV vectors, but to the field of vaccinology in general. In contrast to the copious amounts of information derived from human blood samples, little is known about how routine vaccinations impact activation and immunity at mucosal sites.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
300283
Name
Perciani Catia T
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Immunological Characterization of Varicella Zoster Virus (VZV) as a Replicating Viral Vector for an HIV Vaccine
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Chickenpox Vaccine; Correlates Of Protection; Flow Cytometry; Functional Cure; Herpesvirus; Hiv Vaccine; Immune Activation; Live-Attenuated Recombinant Virus; Polyfunctional T Cell Responses; Varicella-Zoster Virus
Abstract
The Varicella-Zoster virus (VZV) vaccine, also known as chickenpox vaccine, has been used to great success in routine immunizations for over 25 years. Unique aspects of this vaccine may, in fact, be useful in developing a vaccine against HIV. After vaccination against VZV, the virus persists in the body in a dormant state causing silent reactivation throughout a person's life. Although silent, this reactivation boosts the immunity and helps to keep the disease in check. This ability to reactivate may be a key factor that we can take advantage of in an HIV vaccine, where one of the principal hurdles is generating a specialized defence army in constant sentinel at the portal of entry of HIV.
Our group has recently tested this strategy in monkeys using VZV as a "transport" vector carrying a "payload" of genes from SIV (Simian Immunodeficiency Virus) - the monkey version of the AIDS virus. Results of this trial are promising, with about a third of vaccinated monkeys demonstrating complete and sustained SIV viral clearance in what may be termed a "Functional Cure". Understanding the mechanisms associated with this effect are a key component of my research project which insights will be used to improve vaccine design.
Although the human VZV vaccine has a well-described safety record, it is important to further investigate its potential as a vector in an HIV vaccine. To do so, we will assess the level of immune activation following vaccination with the empty VZV vector in a cohort in Kenya. This is a critical question, since HIV infects activated immune cells in the mucosa and, in the absence of induced protective immunity, could pose a safety hazard.
This project has significant implications, not only to the development of novel HIV vectors, but to the field of vaccinology in general. In contrast to the copious amounts of information derived from human blood samples, little is known about how routine vaccinations impact activation and immunity at mucosal sites.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Perciani, Catia T
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~